Brief: Regeneron Pharmaceuticals Announces Positive Phase 3 NIMBLE Trial Results For Cemdisiran In gMG
21/04/2026 18:34
April 21 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: CEMDISIRAN, DOSED SUBCUTANEOUSLY EVERY 12 WEEKS, DEMONSTRATES RAPID, DEEP AND SUSTAINED DISEASE CONTROL IN GENERALIZED MYASTHENIA GRAVIS (GMG) PHASE 3 TRIAL REGENERON PHARMACEUTICALS INC - ANNOUNCES POSITIVE PHASE 3 NIMBLE TRIAL RESULTS FOR CEMDISIRAN IN GMG Source text: ID:nGNX6xB5d5 Further company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)